Keyphrases
Chimeric Antigen Receptor T Cells (CAR-T)
100%
Acute Myeloid Leukemia
66%
T Cells
56%
CD123
50%
JS-K
33%
Acute Lymphoblastic Leukemia
29%
Engager
27%
Natural Killer Cells
26%
Chimeric Antigen Receptor T-cell Therapy
24%
Tisagenlecleucel
22%
Diazeniumdiolate
22%
B-cell Acute Lymphoblastic Leukemia (B-ALL)
22%
Interleukin-15 (IL-15)
22%
IL-7 Receptor
22%
Leukemia
21%
Antitumor Activity
19%
CD19
15%
Pediatric Leukemia
14%
T Cell Activation
14%
Acute Myeloid Leukemia Cells
14%
Pediatric Patients
13%
T Cell Receptor
13%
Cell Infusion
12%
Disease Burden
12%
Transgenic Expression
12%
Aryl
12%
Dinitrophenyl
12%
Engineered T Cells
12%
Clinical Testing
11%
Overall Survival
11%
Bispecific T-cell Engager (BiTE)
11%
SNAr
11%
Glutathione
11%
Glycans
11%
Efficiency Improvement
11%
MAGUK
11%
Nitric Oxide Donors
11%
Childhood Leukemia
11%
Pediatric Acute Lymphoblastic Leukemia
11%
Dual-target
11%
Banana Lectin
11%
Glutathione S-transferase
11%
Epigenetic Drivers
11%
Hemophagocytic Lymphohistiocytosis
11%
Systemic Toxicity
11%
Linked Immunosorbent Assay
11%
Cellular Immunotherapy
11%
Sweet
11%
Genetic Drivers
11%
Malignancy
11%
Immunology and Microbiology
T Cell
81%
Myeloid
64%
Chimeric Antigen Receptor
55%
Chimeric Antigen Receptor T-Cell
48%
Immunotherapy
37%
Chimeric Antigen Receptor Natural Killer Cell
33%
Lectin
22%
B Cell
22%
Natural Killer Cell
21%
CD19
18%
Glycoprotein
18%
Severe Acute Respiratory Syndrome Coronavirus 2
14%
Glycan
13%
Leukemia Cell
13%
Chimeric Antigen Receptor T-Cell Therapy
13%
Transgenics
13%
Disease Burden
12%
Hemophagocytic Lymphohistiocytosis
12%
Stroma
11%
Event Free Survival
11%
P53
11%
Monospecific Antibody
11%
Epstein Barr Virus
11%
Cell Activity
11%
Biological Activity
11%
Interleukin 15
11%
Growth Inhibition
11%
Immunoadsorption
11%
Natural Killer T Cell
11%
Cancer Immunotherapy
11%
Human Cell
11%
Xenograft
10%
Overall Survival
10%
Antineoplastic Activity
8%
Hematopoietic Stem Cell Transplantation
8%
Cytokine Receptor
7%
Tumor Cell
7%
Cytokine
6%
Tumor Antigen
6%
CD34
5%
Immune Checkpoint Blockade
5%
Pancreatic Stellate Cell
5%
Coculture
5%
Glycosylation
5%
Cytokine Release Syndrome
5%
Medicine and Dentistry
Chimeric Antigen Receptor T-Cell
58%
Immunotherapy
39%
T Cell
38%
Chimeric Antigen Receptor T-Cell Immunotherapy
32%
Acute B-Cell Lymphoblastic Leukemia
22%
Cancer
19%
Hematologic Malignancy
18%
Chimeric Antigen Receptor
17%
Disease
16%
Neoplasm
16%
Infusion
16%
Acute Lymphoblastic Leukemia
14%
Malignant Neoplasm
13%
Disease Burden
12%
Hemophagocytic Syndrome
12%
Solid Malignant Neoplasm
11%
Myelodysplastic Syndrome
11%
Childhood Leukemia
11%
Chemokine Receptor
11%
Virus Infection
11%
Event Free Survival
11%
Pediatrics Patient
11%
Epstein Barr Virus
11%
Nitric Oxide
11%
Cancer Immunotherapy
11%
Chimeric Antigen Receptor Immunotherapy
11%
Glycan
11%
Nucleophile
11%
Blood Product
11%
Natural Killer T Cell
11%
Secondary Acute Myeloid Leukemia
11%
Bispecific Antibody
11%
Receptor
11%
Leukemia
10%
Overall Survival
10%
Janus Kinase
8%
Cytokine Release Syndrome
8%
Hematopoietic Stem Cell Transplantation
7%
Glycoprotein
7%
Cancer Treatment
7%
Cytokine Receptor
7%
Acute Myeloid Leukemia
6%
Cell Growth
6%
Clinical Trial
6%
Pediatrics
6%
Tumor Cell
5%
Adoptive Transfer
5%
Immune Checkpoint Blockade
5%
Blinatumomab
5%
